Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1305 · 5 trials · 3 indications
QTcF-QT interval corrected for the RR interval (the time elapsing between two consecutive R waves in the electrocardiogram (ECG)) using the Fridericia formula.For each of 3 consecutive beats (5 consecutive beats if AF) a manual measurement, preferably in lead V2, of QTend intervals was done.The mean QT values of the 3 consecutive beats (5 consecutive beats if AF) were, together with RR intervals, date \& time of the ECG, entered into the eCase Report Form (eCRF).The selected beats had to be marked with calipers and noted together with measured values and calculations on the print-out and signed
Conversion of AF to SR with maintenance of SR maintained for at least 1 minute
To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction.
Maximum of all QTcF values obtained for any given patient from randomisation until the intended end of the study drug period, day 10.
Absolute change, after - before infusion
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD1305 iv infusion |
| 2 | PLACEBO_COMPARATOR | Placebo iv infusion |
| AZD1305 loading dose 250 mg + 125 mg | EXPERIMENTAL | Tablets |
| AZD1305 loading dose 500 mg + placebo | EXPERIMENTAL | Tablets |
| Placebo corresponding to AZD1305 loading dose | PLACEBO_COMPARATOR | Tablets |
| 3 | ACTIVE_COMPARATOR | Digoxin |
| Name | Type | Description |
|---|---|---|
| AZD1305 | DRUG | Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes |
| Placebo | DRUG | iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes |
| Digoxin | DRUG | Tablet, repeated administration |
Inclusion Criteria: * Clinical indication for cardioversion of Atrial Fibrillation, ie a correction of irregular heart rhythm to normal heart rhythm * Current episode of Atrial Fibrillation (ie irregular heart rhythm) lasting up to 3 months at randomisation * Adequate anticoagulation according to i...
Top 5 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | REGN7508, REGN9933 |
| Johnson & Johnson | JNJ | 14 | PHASE3 | Milvexian |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Abelacimab, PKN605 |
| Milestone Pharmaceuticals, Inc. | MIST | 1 | PHASE3 | Etripamil |
| Bayer | BAYRY | 1 | PHASE2 | BAY 3670549 |
AZD1305 was studied for the treatment of atrial fibrillation and atrial flutter, and was also evaluated in patients with left ventricular dysfunction. It is an investigational small molecule that was developed as an intravenous cardioversion agent for restoring normal sinus rhythm in patients with these cardiac arrhythmias.
AZD1305 targets multiple cardiac ion channels: KCNH2, SCN5A, CACNA1C, CACNA1S, CACNA1D, and CACNA1F. It acts as a blocker at these targets, which include potassium, sodium, and calcium channels involved in cardiac electrical activity. This multi-channel blocking profile was intended to stabilize cardiac rhythm.
AZD1305 was developed by AstraZeneca PLC, which trades on the NASDAQ under the ticker AZN. AstraZeneca sponsored the clinical trials of AZD1305, including studies in atrial fibrillation and left ventricular dysfunction.
AZD1305 reached Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. All three completed trials were Phase 2 studies, and no active trials are currently listed.
AZD1305 has been studied in three completed clinical trials. These include NCT00915356, a Phase 2 trial of intravenous cardioversion in atrial fibrillation; NCT00748982, a Phase 2 trial in patients with left ventricular dysfunction; and NCT00643448, a Phase 2 explorative study in atrial fibrillation patients.
AZD1305 is the only name used for this investigational compound in the clinical trial records. No alternative names or synonyms are referenced in the available data.